NewAmsterdam Pharma Company NV Overview
Latest ROE for NewAmsterdam Pharma Company NV: -31.98% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-31.98%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
NewAmsterdam Pharma Company NV (NAMS) currently reports a ROE of -31.98%. That is below the sector sector average of -4.47%. Use the charts on this page to explore NewAmsterdam Pharma Company NV's ROE history and peer comparisons.
NewAmsterdam Pharma Company NV's ROE of -31.98% is lower than the its sector sector average of -4.47%. That is roughly 615.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but NewAmsterdam Pharma Company NV's current -31.98% should be judged against industry norms (sector average: -4.47%) and against NAMS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -31.98%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -4.47%. From there, open related valuation or income-statement pages for NewAmsterdam Pharma Company NV, and consider following NAMS for alerts when major investors trade the stock.
